HeartFlow described the move as a mutual decision a "result of current unfavorable market conditions."
Affiliates of Glenview Capital Management sponsored Longview.
When HeartFlow and Longview announced the SPAC deal plans in July 2021, the merger was valued at .4 billion, with an estimated $400 million in cash after closing.
HeartFlow anticipated $599 million of gross proceeds to accelerate the growth of its non-invasive, personalized cardiac tests.
The company's non-invasive HeartFlow FFRCT analysis uses artificial intelligence to create a personalized three-dimensional heart model.
Clinicians can use the model to evaluate the impact a blockage has on blood flow and determine the best treatment for patients.
The company's HeartFlow Analysis is commercially available in the U.S., the U.K., Canada, Europe, and Japan.
Price Action: LGV shares closed 0.21% higher at $9.73 on Friday.
See more from Benzinga
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.